Cutaneous melanoma · line 1 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | None |
| ID | IND-MELANOMA-NIVO-MAINT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-MELANOMA |
| Sources | SRC-CHECKMATE-067-LARKIN-2019 SRC-ESMO-MELANOMA-2024 SRC-NCCN-MELANOMA-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. line_of_therapy: 1 because nivo maintenance is continuation of 1L pathway after nivo+ipi induction. Missing entity flag: dedicated REG-NIVO-MAINTENANCE-MELANOMA — author in PROD-2.
Used By
No reverse references found in the YAML corpus.